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Abstract  
Pepducins are cell-penetrating, membrane-tethered lipopeptides designed to target the 
intracellular region of a G protein-coupled receptor (GPCR) in order to allosterically modulate the 
receptor’s signaling output. In this proof-of-concept study, we explored the pain-relief potential of 
a pepducin series derived from the first intracellular loop of neurotensin receptor type 1 (NTS1), 
a class A GPCR that mediates many of the effects of the neurotensin (NT) tridecapeptide, including 
hypothermia, hypotension and analgesia. We used BRET-based biosensors to determine the 
pepducins’ ability to engage G protein signaling pathways associated with NTS1 activation. We 
observed partial Gaq and Ga13 activation at a 10 µM concentration, indicating that these pepducins 
may act as allosteric agonists of NTS1. Additionally, we used surface plasmon resonance (SPR) 
as a label-free assay to monitor pepducin-induced responses in CHO-K1 cells stably expressing 
hNTS1. This whole-cell integrated assay enabled us to subdivide our pepducin series into three 
profile response groups. In order to determine the pepducins’ antinociceptive potential, we then 
screened the series in an acute pain model (tail-flick test) by measuring tail withdrawal latencies 
to a thermal nociceptive stimulus, following intrathecal (i.t.) pepducin administration (275 
nmol/kg). We further evaluated promising pepducins in a tonic pain model (formalin test), as well 
as in neuropathic (Chronic Constriction Injury) and inflammatory (Complete Freund’s Adjuvant) 
chronic pain models. We report one pepducin, PP-001, that consistently reduced rat nociceptive 
behaviors, even in chronic pain paradigms. Finally, we designed a TAMRA-tagged version of PP-
001 and found by confocal microscopy that the pepducin reached the rat dorsal root ganglia post 
i.t. injection, thus potentially modulating the activity of NTS1 at this location to produce its 
analgesic effect. Altogether, these results suggest that NTS1-derived pepducins may represent a 
promising strategy in pain-relief. 
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1. Introduction 
 
G protein-coupled receptors (GPCRs), alternatively known as seven transmembrane receptors 
(7TMRs), represent the single most successful protein target class in drug discovery. Typically, 30 
– 50% of all approved drugs on the market today modulate this family of cell surface receptors 
(Overington, et al., 2006). In recent years, a number of new pharmacological approaches have 
emerged to further exploit their therapeutic potential. One such strategy is the use of cell-
penetrating, membrane-tethered lipopeptides called pepducins (Covic, et al., 2002). 
Specifically, pepducins are composed of a peptide sequence derived from one of the 
intracellular loops of a target 7TM receptor to which a lipid moiety, most commonly a palmitic 
acid, is conjugated at the N-terminal end. Here, the palmitate fulfills the role of a tether which 
effectively anchors the peptide to the cell membrane and enables its translocation toward the 
cytosolic phospholipid leaflet, where it acts at the intracellular receptor-effector interface to 
modulate receptor signaling. Pepducins can act as allosteric agonists or allosteric modulators of 
their cognate receptors, potentially accessing unique receptor conformations that are unavailable 
with traditional orthosteric ligands (Carr III & Benovic, 2016). Since its first introduction by Covic 
et al. in 2002, pepducin technology has been applied to the study of more than a dozen 7TMRs in 
a variety of disease paradigms, including cardiovascular disease, cancer, angiogenesis, 
inflammation, sepsis and asthma (Zhang, et al., 2015a; Tressel, et al., 2011). Notably, a protease-
activated receptor 1 (PAR1)-derived pepducin called PZ-128 will soon complete a phase 2 clinical 
trial as a novel antiplatelet agent, indicating that pepducins may constitute promising therapeutics 
(Gurbel, et al., 2016).  
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Nevertheless, relatively little is known about the pepducin mode of action, and there is a need 
to further study pepducin actions in new receptor systems and physiological conditions. In 
particular, the potential applications of the pepducin approach to pain treatment remain largely 
unexplored. To date, very few studies have administered pepducins to rodents in a pain context, 
and these center almost exclusively around a PAR4-derived pepducin (P4pal-10), used as a tool to 
decipher the role of the PAR4 receptor in pain and inflammation (McDougall, et al., 2009; Russell, 
et al., 2009; Annahazi, et al., 2009). To our knowledge, this study is the first to evaluate pepducins 
in a chronic pain paradigm. 
From the perspective of pain-relief, neurotensin receptor type 1 (NTS1) is a particularly 
interesting GPCR target candidate. NTS1 belongs to the rhodopsin-like family of 7TMRs (Class 
A) (Tanaka, et al., 1990; Vita et al., 1993) and is expressed peripherally in the gut (Azriel & 
Burcher, 2001), in certain cardiac and endothelial cells (Tanaka, et al., 1990; Schaeffer, et al., 
1995), and in pain-related regions of the central nervous system, such as the periaqueductal gray, 
the superficial laminae of the spinal cord dorsal horn, and the dorsal root ganglia (DRGs) (Roussy 
et al., 2008). Consistent with its expression pattern, NTS1 activation has been linked to a wide 
range of physiological effects, such as hypotension (Rioux, et al., 1982), ileum contraction and 
relaxation (Carraway and Mitra, 1994), hypothermia (Feifel, et al., 2010), and, notably, analgesia 
(Pettibone, et al., 2002; Roussy, et al., 2008). Endogenously, it is activated by the neurotensin (NT) 
tridecapeptide (Carraway & Leeman, 1973), which also mediates its effects via another 7TMR 
(NTS2) and a Type 1 transmembrane monomeric glycoprotein (NTS3/sortilin) (Mazella & 
Vincent, 2006). When administered centrally to rodents, NT is known to produce a very potent 
analgesic action. Indeed, on a molar basis, NT is more potent than morphine at producing 
antinociception (Nemeroff, et al., 1979). Furthermore, this antinociceptive effect appears to be 
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independent of the opioid system, as the opioid receptor antagonists naloxone and naltrexone have 
no effect on NT-mediated antinociception (Clineschmidt & McGuffin, 1977). Furthermore, our 
research team has shown that NTS1 agonists can effectively reverse nociceptive behaviors in rat 
models of acute and tonic pain (Roussy, et al., 2008), as well as in chronic neuropathic pain models 
(Guillemette, et al., 2012). Until now, no pepducins have been developed to target NTS1.  
Herein, we provide proof-of-concept data highlighting the potential of the pepducin approach 
in the field of pain research. For this study, we designed and synthesized a pepducin series derived 
from the first intracellular loop of NTS1, which we then screened in BRET-based and label-free 
cellular assays monitoring G protein activation and whole-cell integrated responses, respectively. 
We further evaluated the antinociceptive potential of these pepducins for different types of pain, 
and hereby report a pepducin that consistently reduced rat nociceptive behaviors, when injected 
intrathecally (i.t.). 
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2. Materials and Methods 
 
2.1 Materials 
In order to perform the experiments described here, we obtained the NTS1 antagonist SR48692 
from R & D Systems, Inc. (Minneapolis, MN, USA). We synthesized the compounds NT(8-13), 
and our NTS1-derived pepducin series at the peptide synthesis facility of the Université de 
Sherbrooke (http://www.usherbrooke.ca/ips/en/platforms/psp/). This series consists of five main 
pepducins (NTS1-ICL1-PP-001 to NTS1-ICL1-PP-005), a non-palmitoylated control (NTS1-
ICL1-NP-001), a pepducin with a scrambled peptide sequence (NTS1-ICL1-PP-SCR-001), as well 
as a TAMRA-labeled pepducin (NTS1-ICL1-FP-001). The specific peptide sequences are 
provided in Table 1. The protected amino acids and TentaGel R-RAM resins used in their 
synthesis were obtained from ChemImpex International (Wood Dale, IL, USA). All other 
chemicals and reagents involved in peptide and pepducin synthesis were obtained from Sigma-
Aldrich (Oakville, ON, Canada) or Fisher Scientific (Montreal, QC, Canada). DMEM-F12, 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), penicillin-streptomycin-glutamine, 
fetal bovine serum (FBS), gentamycin G418, phosphate-buffered solution (PBS), Hank’s balanced 
salt solution (HBSS), trypsin-EDTA 0.25% were all obtained from Wisent (St. Bruno, QC, 
Canada).  
 
2.2 Pepducin synthesis 
The ICL1-derived pepducin series was synthesized using standard CàN solid-phase peptide 
synthesis. The peptide chains for each of the pepducins in this series were synthesized on a 0.1 
mmol scale using manual solid phase peptide synthesis. Peptide synthesis was performed in 6 mL 
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polypropylene cartridge with 20 μm PE frit from Applied Separations (Allentown, PA, USA). The 
6 mL reactors were shaken (∼180 rpm) on New Brunswick Scientific orbital shaker. To perform 
these syntheses, Rink Amide resins (Chem-Impex, Wood Dale, IL, USA) with a loading capacity 
of 0.51 meq/g was used. As a first step, the Fmoc-protecting group from the Rink Amide resin was 
removed using 50% piperidine in DMF for 2 cycles of 10 minutes. The solvent was subsequently 
filtered, and the resin was washed with alternative 2-propanol and dichloromethane (DCM, 5 mL) 
cycles, and 3 final cycles of consecutive DMF (3x8 mL). Kaiser test was performed to ensure 
removal of the Fmoc group then the deprotected resin was reacted with the first Fmoc N-protected 
amino acid (5 eq.) in the presence of HATU (5 eq.), N,N-diisopropylethylamine (10 eq.) in DMF 
(2 mL) for at least 2 hours. The resin was washed after each coupling and deprotection step by 
shaking 5 min in DMF (2 × 5 mL), then with three alternative washing cycles of 2-propanol (5 
mL) or DCM (5 mL). The rest of the synthesis for the peptide elongation was performed as 
indicated above. For difficult coupling, we used microwave-assisted synthesis and COMU for 
more efficient peptide coupling. The completion of the coupling reaction was assessed using the 
Kaiser test. 
In the case of the non-palmitoylated control, the peptide was cleaved from the resin upon 
sequence completion, following removal of the last Fmoc protecting group via standard 
deprotection conditions and washes. In the case of the pepducins, the palmitic acid was coupled to 
the free N-terminal end of the peptide sequence. The resin was again submitted to the Fmoc de-
protection steps and dried with diethyl ether. Palmitic acid (5 eq.) and HATU (5 eq.) were 
dissolved in an anhydrous NMP/DCM (1:1) mix followed by DIPEA (10 eq.). The coupling 
mixture was then added to the reaction vessel and shaken overnight at room temperature. The resin 
was washed extensively after coupling with three alternate cycles of 2-propanol (5 mL) or DCM 
 9 
(5 mL). Final resin wash was done in diethyl ether prior to cleavage. For the synthesis of the 
TAMRA fluorescent pepducin (NTS1-ICL1-FP-001), 2-(((9H-fluoren-9-
yl)methoxy)carbonylamino)octadecanoic acid  was purchased from Sigma-Aldrich (Oakville, ON, 
Canada), and was incorporated to the peptide as an amino acid using procedures previously 
described. Following the deprotection of the Fmoc, using the standard deprotection protocol, the 
fluorescent probe 5(6)- Carboxytetramethylrhodamine (5(6)-TAMRA, 4 eq., EMD) was coupled 
overnight to the free amine using the same approach described for palmitic acid. 
Peptides were cleaved using 95% TFA, 2.5% TIPS, 2.5% H2O for at least 2 hours to provide 
the crude pepducins. The resin suspension was filtered through cotton wool and the peptide 
precipitated in a 50 mL Falcon tube in tert-butyl methyl ether (TBDME) at 0 °C. The suspension 
was centrifuged to a pellet for 20 minutes at 1500 rpm and the filtrate was removed by decantation. 
The pellet was placed under high vacuum to remove residual traces of solvent, then resuspended 
in water/acetonitrile and lyophilized to a powder. A sample of the crude pepducin was analyzed 
by UPLC/MS (Waters UPLC system coupled with a SQ detector 2 and a PDA eλ detector, coupled 
to an Acquity UPLC BEH C18 column, 2.1 mm X 50 mm, 1.7 µm spherical size). If the desired 
mass was displayed by the UPLC/MS, usually represented as [M+2]/2 or [M+3]/3, the compound 
was purified by MS-triggered HPLC (Autosampler 2707, quaternary gradient module 2535, UV 
detector 2489, fraction collector WFCIII, from Waters (Milford, MA, USA)), using a C18 column 
(250 mm X 21.2 mm, 5 µm spherical size). UPLC chromatograms were recorded on a Waters 
Acquity H class using the following gradient: water + 0.1% TFA and acetonitrile (0 → 0.2 min, 
5% acetonitrile; 0.2 → 1.5 min, 5% → 95%; 1.5 → 1.8 min, 95%; 1.8 → 2.0 min, 95% → 5%; 
2.0 → 2.5 min, 5%). The crude pepducin (30-60 mg) was dissolved using sonication in 3 mL of a 
DMSO:ACN:H2O mix (1:1:1). The pepducins were purified using variable gradients adapted to 
 10 
the observed analytical retention time; fractions containing the desired mass were combined and 
lyophilized. The lyophilized pepducins retrieved with 95% purity were then dissolved in 100% 
DMSO. Stock solutions were prepared for biological assays at 10 mM concentrations. The 
fluorescent pepducin was kept away from light throughout all the synthesis, purification and 
storage process. 
 
2.3 Cellular assays 
2.3.1 Cell culture and transfections 
The biological assays used to characterize the in vitro behavior of our pepducin series were 
performed with Chinese Hamster Ovarian (CHO-K1, CCL-61 from ATCC, Manassas, VA) cells. 
The cells were cultured in a DMEM-F12 medium containing 20 mM HEPES, 10 % FBS, and 
penicillin (100 U/mL)-streptomycin (100 µg/mL)-glutamine (2 mM). They were maintained at 
37oC and 5% CO2, in a humidified atmosphere. CHO-K1 cells stably expressing hNTS1, 
purchased from Perkin Elmer (Montreal, QC, Canada), were also cultured in the same conditions 
as above, but further supplemented with 0.4 mg/mL of the geneticin (G418) antibiotic. All cell 
lines were used between passages 5 and 20. Certain cellular assays required the transfection of 
cDNA plasmids, for transient expression of recombinant proteins. The transfection procedure was 
as follows: 1.5 x 106 cells were seeded onto 100 mm2 cell culture dishes, and, 24 hours later, 
received a total of 12 µg cDNA, prepared in Opti-MEM serum-free media along with the 
transfection agent polyethylenimine (PEI) at a 3:1 ratio (PEI : DNA), as previously described 
(Erhardt, et al., 2006). 
 
2.3.3 G protein activation cellular assay 
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The pepducins’ ability to activate NTS1-associated G protein signaling pathways was assessed 
using biosensors based on Bioluminescence Resonance Energy Transfer (BRET) technology. 
BRET is defined as a transfer of energy that occurs between an enzymatic donor and a fluorescent 
acceptor when these two proteins are at a distance closer than 100 Å and in a favorable orientation, 
following activation of the donor by degradation of its substrate. The BRET-based biosensors used 
here were designed to directly measure the dissociation of Ga and Gg protein subunits, and were 
generously provided by Dr. Michel Bouvier (Department of Biochemistry and IRIC, Université de 
Montréal, Montréal, QC, Canada), as a member of the CQDM team (Drs. M. Bouvier, T. Hébert, 
S.A. Laporte, G. Pineyro, J.-C. Tardif, E. Thorin and R. Leduc). In the assays performed in this 
study, 1.5 x 106 CHO-K1 cells were seeded into 100 mm2 cell culture dishes and transfected 24 
hours later according to the procedure described above. The cells were transfected with either of 
the following biosensor couples: hNTS1, Gαq-RlucII, Gb1 and Gg-GFP10 (Breton, et al., 2010); or 
hNTS1, Gα13-RlucII, Gb1 and Gg-GFP10 (Quoyer, et al., 2013; Demeule, et al., 2014). Cells were 
detached 24 hours post-transfection using trypsin-EDTA 0.25% and were seeded into white 
opaque 96-well plates (BD Falcon, Corning, NY, USA) at a concentration of 50 000 cells/well. 
On the final day of the experiment, the adhered cells were washed once with 100 µL of PBS and 
stimulated with 1 µM of NT(8-13) or 10 µM of the pepducins, prepared in a 100 µL volume of 
HBSS (20 mM HEPES). The cells were then stimulated with coelenterazine 400A (5 µM), 
incubated at 37oC for 15 minutes, and read on a GENios Pro plate reader (Tecan, Durham, NC, 
USA) using a BRET2 filter set (400-450 nm and 500-550 nm emission filters).  
For each well, a BRET2 ratio was determined by dividing the GFP10-associated light emission 
by RlucII-associated light emission. The data was subsequently normalized relative to NT(8-13); 
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values for non-treated cells were set as 0% pathway activation, and those for cells treated with 1 
µM NT(8-13) were set as 100% pathway activation.  
 
2.3.2 Surface plasmon resonance cellular assay 
We monitored the global response of living cells to molecular stimuli by surface plasmon 
resonance (SPR). As previously described in Cuerrier, et al. (2008) and in Lavenus, et al. (2018), 
we prepared a SPR substrate that consisted of a glass support upon which a gold layer (48 nm) was 
deposited on top of a chromium adhesion layer (3nm), followed by a 5 min exposure with poly-L-
lysine 0.01% (Sigma, Oakville, Canada) to promote cell adhesion. CHO-K1 cells stably expressing 
hNTS1 (CHO-hNTS1) or CHO-K1 wild-type cells were seeded at a density of 100 000 cells/cm2 
onto 60 mm petri dishes containing the SPR substrate and allowed to grow for two days in a 
DMEM-F12 medium supplemented with HEPES, FBS and antibiotics. They were starved for one 
day in DMEM-F12 media (without FBS) prior to the experiment.  Measurements were performed 
at 90% confluency, as evaluated by contrast microscopy. Once placed on the SPR apparatus, the 
media was replaced with Leibovitz’ L15 media. Once the incident angle for optimal SPR detection 
was determined, a 10-min baseline was recorded to ensure that the cells reached a steady state 
before compound incubation. The CHO-hNTS1 cells were then stimulated with 10 µM 
concentrations of NT(8-13) or of the ICL1-derived pepducin series. Cells were subsequently 
monitored for a period of 30 minutes, and data were acquired at 1-second intervals. The results for 
this experiment are plotted in terms of reflectance variation units (RVU) over time, for which 1 
RVU represents 0.1% variation in total reflectance and the time is measured in seconds.  
 
2.4 Behavioral studies 
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2.4.1 Animals, housing and habituation 
All animal procedures were approved by the Ethical and Animal Care Committee of the 
Université de Sherbrooke (protocol number 035-18) and were in accordance with policies and 
directives of the Canadian Council on Animal Care. They further comply with the ARRIVE 
guidelines. Adult male (250−300 g) Sprague−Dawley rats (Charles River Laboratories, St-
Constant, QC, Canada) were maintained on a 12-hour light/dark cycle with free access to food and 
water. Prior to the behavioral studies, the rats were acclimatized for 4 consecutive days to the 
animal facility and for 3 consecutive days to the experimental conditions of each test. 
 
2.4.2 I.t. administration of NTS1-derived pepducins 
In all the behavioral tests reported here, the compounds were administered via i.t. injection. 
Rats were lightly anesthetized with 2.5% isofluorane (Abbott Laboratories, Montreal, QC, 
Canada). Subsequently, a 25 µL volume of ICL1-derived pepducins at a 275 nmol/kg was 
administered alone or in conjunction with the SR48692 antagonist (10 µg/kg), by injection into 
the subarachnoid space between lumbar vertebrae L5 and L6, using a 27 G 1/2 needle. Pepducins 
were diluted in a vehicle composed of physiological saline, 10% DMSO and 20% polyethylene 
glycol 4000 (PEG4000). Control animals were injected with the vehicle alone. At these doses, no 
sedation or visible side effects were observed. 
 
2.4.3 Acute pain model (tail-flick test)  
The effect of the ICL1-derived pepducins on acute thermal nociception was assessed using the 
tail-flick test. This test involves measuring the latency (in seconds) for a rat to withdraw its tail 
from an acute nociceptive stimulus. Here, this stimulus was a water bath maintained at 52°C. The 
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effects of the pepducins’ and of the vehicle were assessed immediately following i.t. injection. The 
thermal threshold latencies were determined every 10 min for up to 1 hour after drug injection. A 
cut-off was set at 10 s to avoid tissue damage.  
 
2.4.4 Tonic pain model (formalin test) 
Antinociception was also assessed using the formalin test as a model of tonic pain. Following 
i.t. injection of the vehicle or test compounds, acclimated male Sprague-Dawley rats received a 50 
μL subcutaneous injection of diluted 2% formaldehyde (i.e., 5% formalin, Fisher Scientific, 
Montreal, QC, Canada) into the plantar surface of the right hind paw. The rats were then placed in 
clear plastic chambers (30 cm × 30 cm × 30 cm) positioned over a mirror angled at 45° in order to 
allow an unobstructed view of the paws. The rats’ behaviors were observed for a 60-minute period. 
The intra-plantar injection of formalin produced the biphasic nociceptive response typical of this 
tonic pain model. The two distinct phases of spontaneous pain behaviors that occur in rodents are 
proposed to reflect a direct effect of formalin on sensory receptors (acute phase; 0-9 min post-
injection) and a longer-lasting pain due to inflammation and central sensitization (inflammatory 
phase; 21-60 min post-injection).  
Nocifensive behaviors were assessed using a weighted score method, as previously described 
(Coderre, et al., 1993). Following the injection of formalin into the right hind paw, the 
experimenter measured the time spent in each of four behavioral categories: 0, the injected paw is 
comparable to the contralateral paw; 1, the injected paw has little or no weight placed on it; 2, the 
injected paw is elevated and is not in contact with any surface; 3, the injected paw is licked, bitten, 
or flinched. The behaviors believed to represent higher levels of pain intensity were given higher 
weighted scores. The weighted average pain intensity score ranging from 0 to 3 was then calculated 
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by multiplying the time spent in each category by the category weight, summing these products, 
and dividing by the total time in a given time interval. The pain score was thus calculated from the 
following formula (1T1 + 2T2 + 3T3)/180 where T1, T2, and T3 are the duration (in seconds) 
spent in behavioral categories 1, 2, or 3, respectively, during each 180 s block (Dubuisson & 
Dennis, 1977). The total area under the curve (AUC) for the inflammatory phase was calculated 
between 21−60 min.  
 
2.4.5 Chronic neuropathic pain model (chronic constriction injury model) 
The pepducins’ analgesic potential was further assessed in chronic pain models. Neuropathic 
pain was induced through chronic constriction injury (CCI) of the sciatic nerve, as previously 
described (Bennett & Xie, 1988). Briefly, under isoflurane anaesthesia (5% in O2, Abbott 
Laboratories, Montreal, QC, Canada), the rat was placed in left lateral recumbency, and a 2.5 cm 
longitudinal skin incision was made starting at the sciatic notch. The right common sciatic nerve 
was exposed at the midthigh level by blunt dissection through the biceps femoris muscle. Proximal 
to the sciatic nerve’s trifurcation, 7 mm of nerve was freed from adhering tissues, and four ligatures 
were loosely tied around it with about 1 mm of spacing (4.0 Sofsilk suture). The wound was then 
closed in layers and the skin was sealed with 4.0 silk sutures. This right side was defined as the 
operated-ipsilateral limb, while the non-operated leg (left) represented the contralateral side. Great 
care was taken to tie the ligatures such as the diameter of the sciatic nerve was seen to be just 
barely constricted, when viewed under a dissecting microscope. Rectal temperature was 
maintained at 37 ± 1°C by using a heating pad and ophthalmic ointment was used to prevent 
corneal desiccation. Rats were housed individually for 48 h following surgery.  
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Subsequently, mechanical allodynia was evaluated bilaterally using the von Frey test as 
described previously (Chaplan, et al., 1994). To measure rat hind paw mechanical threshold, 
animals were placed into compartment enclosures in a test chamber with a framed metal mesh 
floor. Sensitivity to light touch was then determined using the up-down method of Dixon (1980) 
on days 7 and 14 post-surgery. Testing was initiated with a 2.0 g von Frey hair. In the absence of 
a paw withdrawal response, a stronger stimulus was used. In the event of paw withdrawal, a weaker 
stimulus was applied. Four additional stimulations with weaker/stronger hairs were performed 
following the initial response. The cut-off was set at the 15.0 g hair. The 50% g threshold was 
calculated using the method described in Chaplan et al. (1994) with a d value of 0.197. 
 
2.4.6 Chronic inflammatory pain model (complete Freund’s adjuvant model) 
Under isoflurane anesthesia (5% in O2, Abbott Laboratories, Montreal, QC, Canada), 100 μL of 
complete Freund’s Adjuvant (CFA) emulsified 1:1 with saline 0.9% and containing 4 mg/mL of 
dessicated Mycobacterium butyricum was injected in the plantar surface of the right hind paw of 
male Sprague-Dawley rats. Twelve days after CFA administration, the rats received an i.t. 
administration of the vehicle (saline solution, 10% DMSO and 20% PEG) or the pepducin series 
(275 nmol/kg). On days 7 and 12 post-CFA, mechanical allodynia was assessed with the up-down 
method of Dixon (1980), as described above for the CCI animals.  
 
2.5 Detection of the fluorescent pepducin in rat dorsal root ganglion cells 
Male Sprague-Dawley rats were i.t. injected with the TAMRA-tagged pepducin (FP-001) at a 
275 nmol/kg dose. Control animals were injected with vehicle alone (saline, 10% DMSO, 20% 
PEG4000). Twenty minutes post-injection, the rats were anesthetized with 5% isoflurane and 
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euthanized. The dorsal root ganglia (DRGs) of the L4 to L6 lumbar vertebrae were rapidly isolated, 
post-fixed overnight in 4% paraformaldehyde at 4℃, and then cryoprotected in a 30% sucrose 
phosphate-buffered solution (PBS) at 4℃. Tissues were frozen at −20℃ in Tissue-Tek O.C.T. 
Compound obtained by Sakura Finetek USA Inc. (Torrance, CA, USA) and then sectioned at 
20 µm with a cryostat (Leica CM1860UV, Leica Biosystems, Concord, ON, Canada). Sections 
were washed twice in PBS for 10 min and incubated with DAPI staining (1:16000 dilution) for 10 
min at room temperature. They were then rinsed twice with PBS for 10 min. The sections were 
mounted on SuperFost Plus slides (VWR, Mississauga, ON, Canada) and cover-slipped with 
Prolong Diamond Antifade Mountant (Thermofisher, Waltham, MA, USA). Images were acquired 
on a Leica DMI8 epifluorescence microscope (Leica Microsystems, Toronto, ON, Canada), using 
the same acquisition parameters (gain, exposure time). Captured images were analyzed using 
ImageJ software. Three animals per experimental condition were analyzed.  
 
2.6 Data and statistical analysis 
All data obtained for this study was plotted onto graphs using Graphpad Prism 8 software (La 
Jolla, CA, USA) and represent the mean ± SEM of multiple independent experiments. In the BRET 
experiments, pepducins were tested a minimum of three times in duplicate. In the case of the 
cellular SPR assay, a minimum of six independent experiments were performed for each condition. 
For all in vivo behavioral tests, group sizes were determined as n ≥ 6. Animals were randomly 
assigned to vehicle or to pepducin-treated groups by block randomization. Specific n values are 
supplied in each figure legend. In order to compare the mean values between animal groups, two-
way ANOVA tests were performed on behavioral data, with Tukey’s or Sidak’s correction for 
multiple comparisons. In the case where we compared the mean area under the curve between the 
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vehicle and pepducin-treated groups, a Kruskal-Wallis test with Dunn’s correction for multiple 
comparisons was performed. Statistical differences are depicted in the figures by asterisks (*, p < 
0.05; **, p < 0.01; ***, p < 0.001; ****, p <0.0001).  
  
 19 
3. Results and Discussion 
 
3.1 Pepducin design 
In order to determine whether or not pepducins targeting the NTS1 receptor may represent a 
valid strategy in pain relief, we designed and synthesized a pepducin series derived from the first 
intracellular loop domain (ICL1) of the NTS1 receptor. This series includes five main pepducins, 
a non-palmitoylated control, and a control pepducin with a scrambled peptide sequence. The 
peptide sequence for the first pepducin in our series (NTS1-ICL1-PP-001) corresponds to the full 
14 amino acid sequence of the ICL1 domain of the human NTS1 receptor, as defined on the 
Uniprot database (ID: P30989, https://www.uniprot.org/uniprot/P30989). For the following 
pepducins in our series, this peptide sequence was sequentially truncated by increments of two C-
terminal amino acids in order to identify a minimal biologically active fragment. The specific 
amino acid sequences for the full-length and truncated pepducins (Supplementary Scheme S1) 
are provided in Table 1. As there is no consensus regarding pepducin nomenclature, we identified 
these pepducins by a code detailing the target receptor (NTS1), the intracellular domain used as a 
template (ICL1), and the state of the peptide (i.e. PP = palmitoylated peptide, NP = non-
palmitoylated peptide, FP = fluorophore-tagged palmitoylated peptide, Supplementary Scheme 
S2). Hereafter, the pepducins will be referred to in this article only by their abbreviated names (i.e. 
PP-001, PP-002, etc.).  
The decision to use ICL1 as a starting point was primarily based on the fact that, contrarily to 
some of the other loops, it has a peptide sequence that is identical between the human, rat and 
mouse receptors, and we hypothesized that this would represent an experimental advantage when 
translating our findings between in vitro and in vivo models. Also, there are comparatively few 
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ICL1-based pepducins described in the literature to date (Zhang, et al., 2015a; O’Callaghan et al., 
2012; Tressel, et al., 2011).  
 
Table 1: Peptide sequences of the ICL1-derived NTS1 pepducin series 
Compound Abbreviation Amino Acid Sequence 
NT(8-13) -- H- R R P Y I L -OH 
NTS1-ICL1-PP-001 PP-001 Palmitoyl- A R K K S L Q S L Q S T V H -NH2 
NTS1-ICL1-PP-002 PP-002 Palmitoyl- A R K K S L Q S L Q S T -NH2 
NTS1-ICL1-PP-003 PP-003 Palmitoyl- A R K K S L Q S L Q -NH2 
NTS1-ICL1-PP-004 PP-004 Palmitoyl- A R K K S L Q S -NH2 
NTS1-ICL1-PP-005 PP-005 Palmitoyl- A R K K S L -NH2 
NTS1-ICL1-NP-001 NP-001 H- A R K K S L Q S L Q S T V H -NH2 
NTS1-ICL1-PP-SCR-001 PP-SCR-001 Palmitoyl- L V Q R L T A K S S K Q H S -NH2 
NTS1-ICL1-FP-001 FP-001 TAMRA- Octadecanoyl- A R K K S L Q S L Q S T V H -NH2 
 
3.2 NTS1-derived pepducins activate NTS1-related G protein signaling pathways 
In order to determine whether these ICL1-derived pepducins were biologically active, we first 
explored their ability to engage the signaling pathways associated with NTS1 activation. 
Classically, the NTS1 receptor has been linked to the coupling and activation of the Gαq protein, 
known to initiate the cleavage of phosphatidyl inositol biphosphate (PIP2) via the activation of 
phospholipase C, leading to the intracellular release of inositol triphosphate (IP3) and Ca2+ (Amar, 
et al., 1987; Schaeffer, et al., 1995; Choi, et al., 1999). However, our team and others have shown 
that, when activated, NTS1 may engage multiple signaling pathways, including the Gαs, Gαi, Gαo, 
and Gα13 protein signaling pathways, as well as the recruitment of b-arrestins 1 and 2 (Besserer-
Offroy, et al., 2017; Hwang, et al, 2010; Gailly, et al., 2000; Oury-Donat, et al., 1995). In this 
study, we thus screened our pepducin series in Gαq and Gα13 signaling pathways, specifically. G 
protein activation was monitored using biosensors based on Bioluminescence Resonance Energy 
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Transfer (BRET) technology, which consist of Gα subunits tagged with a Renilla luciferase 
(RlucII) donor and Gγ subunits tagged with a GFP10 acceptor.  
Here, the experimental paradigm was to stimulate CHO-K1 cells transiently expressing the 
BRET-based biosensors and the hNTS1 receptor with either NT(8-13) (1 µM) or the ICL1-derived 
pepducins (10 µM), and to monitor G protein dissociation over a 30-minute time period. Note that 
the C-terminal hexapeptide fragment of NT, NT(8-13), corresponds to the minimal biologically 
active fragment (St-Pierre, et al., 1981), and has been reported to promote NTS1 signaling in an 
identical fashion to the full-length NT (Besserer-Offroy, et al., 2017). In Figure 1A and 1B, we 
show G protein activation for each condition 15 minutes post-stimulation. We observed partial 
Gαq protein activation by the pepducins PP-001 to PP-005, ranging in magnitude from 30 ± 8% 
activation (PP-001) to 52 ± 15% activation (PP-005). We observed a greater Gα13 protein 
activation, ranging in values from 33 ± 2% (PP-001) to 98 ± 3% activation (PP-003). Importantly, 
treatment with NP-001, PP-SCR-001 or palmitate alone resulted in no G protein activation for both 
assays. Furthermore, no G protein activation was observed in mock CHO-K1 cells lacking hNTS1 
receptor expression (Supplementary Figure S1). 
These findings suggest that our NTS1-derived pepducins can act as allosteric agonists of the 
receptor by promoting NTS1-related signaling. Admittedly, this agonist effect is only partial, 
compared to NT(8-13), when tested at a high concentration (10 µM). We chose to screen our 
pepducins at this concentration, as the reported potencies for pepducin agonists are generally much 
lower than for orthosteric agonists. For example, the CXCR4-derived pepducin, ATI-2341, has 
been shown to stimulate the Gai1 signaling pathway with an EC50 of 208 ± 70 nM, while CXCR4’s 
endogenous ligand (SDF-1) promotes Gai1 signaling with an EC50 of 0.25 ± 0.06 nM (Quoyer, et 
al., 2013). Likewise, the b2AR-derived ICL3-9 pepducin produces cAMP with a 4.7 ± 0.1 µM 
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potency (Carr III et al., 2014), whereas b2AR’s endogenous ligand (isoproterenol) promotes 
cAMP production with an EC50 of 8.23 ± 0.15 nM (van der Westhuizen, et al., 2014). To our 
knowledge, the most potent pepducin described so far is ICL1-9, also derived from b2AR, which 
recruits b-arrestins with an EC50 of 96 ± 14 nM (albeit only with partial efficacy) (Carr III, et al., 
2016), compared to 20 ± 5 nM for isoproterenol (Hamden, et al., 2005). Other pepducins from the 
same ICL1-based b2AR pepducin series presented with EC50 values of 1-2 µM (ICL1-4 = 1.9 ± 
0.5 µM; ICL1-11 = 1.7 ± 0.5 µM and ICL1-20 = 1.1 ± 0.3 µM). When interpreting these functional 
potencies, the particular mode of action of pepducins should be taken into account, as pepducins 
must first cross the membrane barrier in order to modulate receptor activity. This mechanism of 
action by which pepducins passively flip between the outer and inner leaflets of the cell membrane 
in order to enter into the cell has been confirmed by numerous studies. In 2007, Wielders and 
colleagues used a FRET-based assay and differentially labeled phospholipids to demonstrate that 
PAR1 pepducins are present in the outer and inner leaflets of the plasma membrane (Wielders, et 
al., 2007). Tsuji and colleagues developed their own FRET probes based on the PAR1-derived 
P1pal-13 pepducin, with a fluorescent switch component that enabled them to observe transbilayer 
pepducin movements using live cell imaging (Tsuji, et al., 2013). As this process is passive and 
bidirectional, we cannot know what proportion of the dose administered functionally interacts with 
the target receptor at any given time-point. Determinations of pepducins’ potency and efficacy, 
therefore, cannot depend solely on the affinity of a given pepducin for its cognate receptor or on 
factors such as cell-type and environment, but must also include considerations such as the rate at 
which pepducins cross the membrane barrier, and how they are distributed between the inner and 
outer leaflets of the cell membrane. 
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3.3 NTS1-derived pepducins induce NTS1-dependent dynamic mass redistribution responses in 
a cell monolayer 
While the BRET experiments indicated that our pepducins could activate NTS1-related 
signaling pathways, we recognized that NTS1 has a large signaling repertoire, and that establishing 
pepducin signaling profiles by monitoring the activation of individual signaling pathways would 
be a complex task. We therefore sought to establish global pepducin response profiles by 
measuring a cellular response that results from the integration of all molecular events within the 
cell. Consequently, we monitored the whole-cell integrated responses of a CHO-hNTS1 cell 
monolayer by surface plasmon resonance (SPR), in response to 10 µM of NT(8-13) and of each of 
the pepducins in our series (Figure 2). Briefly, this optical sensing technique detects changes in 
the refractive index of a laser as it passes through a prism and is reflected off a gold-plated 
substrate, upon which living cells have been seeded (Chabot, et al., 2009). Molecular 
reorganization and corresponding dynamic mass redistribution (DMR) that occur in the basal 
portion of the cell monolayer are detected as variations in reflectance (RVU), which correspond to 
cellular activity such as cytoskeleton remodeling, cell spreading, and cell-cell or cell-substrate 
adhesion or tension (Cuerrier, et al., 2008). This non-invasive and label-free technique therefore 
offers the advantage of integrating all the molecular events associated with the activation or 
inhibition of cell signaling activity. 
As can be observed in Figure 2A, the pepducin-treated conditions presented with SPR traces 
that differ greatly from NT(8-13)’s, and from each other’s. Whereas the SPR trace for NT(8-13), 
previously reported by our team (Besserer-Offroy, et al., 2017), is characterized by an initial 
decline in reflectance (-5 ± 1 RVU) and a subsequent increase which, after a brief plateau, reaches 
a maximum reflectance of 27 ± 5 RVU, the SPR traces monitored for our pepducin series are quite 
 24 
different. In the case of PP-001, we observed a robust increase in reflectance reaching a maximal 
amplitude of 80 ± 13 RVU at 400 seconds post-stimulation, followed by a gradual decline in 
reflectance until the end of the experiment. In the case of PP-002 and PP-003, we observed a more 
gradual increase in reflectance which reached values of 90 ± 10 RVU and 126 ± 20 RVU, 
respectively. In the case of PP-004 and PP-005, presented in Figure 2B, a high initial rate of 
change in reflectance was observed, reaching high amplitude plateaus (309 ± 12 RVU and 241 ± 
12 RVU, respectively) within 400 seconds that lasted until the end of the assessment. Based on 
these traces, the pepducin series can be divided into three distinct profile groups (PP-001; PP-002 
and PP-003; PP-004 and PP-005). Due to the integrative nature of the assay, it is difficult to 
delineate the contribution of particular cellular or signaling events associated to the observed 
reflectance profiles. However, the results indicate that there is greater global signaling activity for 
PP-004 and PP-005, compared to PP-002 and PP-003. Also, these results could point toward a 
more specific signaling activity for PP-001. Nevertheless, this SPR experiment confirmed that the 
pepducins are biologically active and induce cellular responses in a NTS1-expressing cell 
population that differ from those of NT(8-13), suggesting that they may stabilize alternate receptor 
conformations than the native ligand, potentially producing very different outcomes. 
As pepducins are lipidated peptides, they could induce cellular toxicity, we thus assessed cell 
viability after a prolonged exposure to PP-001. As shown in Supplementary Figure S2, after 16 
hours of incubation with 10 µM of PP-001, cell viability was comparable to the vehicle treated 
cells suggesting that, despite their physicochemical properties, pepducins do not reduce cell 
viability. 
Importantly, control experiments were performed in which CHO-hNTS1 cells received 10 µM 
of NP-001 and PP-SCR-001, and in which mock CHO-K1 cells received 10 µM of NT(8-13) or 
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the PP-001 pepducin (Figure 2C-F). The SPR signal for each of these conditions remained steady, 
and no detectable changes in reflectance were observed. This key result, which demonstrates that 
receptor expression is required for pepducin action, correlates with what is known for the great 
majority of pepducins. Indeed, pepducins are reported to be receptor-dependent; both PAR4- and 
CXCR4-targeting pepducins, for example, lose their activity when the target receptor is absent 
(Covic, et al., 2002; Tchernychev, et al., 2010). Thus, while much about the pepducin mode of 
action remains unclear, they do appear to act via a direct pepducin-receptor interaction. This 
conclusion is notably supported by work from Janz and colleagues, who used a photochemical 
cross-linking approach to confirm that the ATI-2341 pepducin is a direct binding partner of its 
cognate receptor, CXCR4 (Janz, et al., 2011). Other recent studies have instead successfully 
attempted to visualize pepducin-induced changes in receptor conformation using purified receptor 
systems conjugated to environmentally sensitive fluorophores, such as monobromobimane (Carr 
III, et al., 2014; Zhang, et al., 2015b). Thus, the authors were able to determine that the β2AR-
derived pepducin ICL3-9 induces a unique conformational change in the TM6 region of the 
receptor, one that differs from that of the endogenous agonist isoproterenol (Carr III, et al., 2014). 
Conversely, the PAR1-derived pepducin P1pal-19 appears to induce a similar conformational 
change to PAR1’s TM5 as that induced by the endogenous agonist thrombin (Zhang, et al., 2015b). 
These indications of receptor conformational changes reinforce the idea that the target receptor is 
critical to the pepducin mode of action. We are aware of only one pepducin, a b2-adrenergic 
receptor-derived pepducin named ICL3-8, that is reported to promote Gαs-downstream signaling 
independently of the cognate receptor, and its mechanism of action is yet undetermined (Carr III, 
et al., 2014). 
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3.4 PP-001 and PP-005 significantly reduce acute pain 
Having demonstrated that our pepducins were able to engage G-protein-mediated signaling 
pathways and to produce distinct DMR responses associated with NTS1 activation, we next 
assessed the antinociceptive potential of our pepducins in the tail-flick acute pain assay. We 
measured the latency in the tail withdrawal response of healthy adult male rats to a noxious thermal 
stimulus (a 52oC water bath) following i.t. injection of the pepducins. This pain model is generally 
used as a tool to screen for analgesics, of which the most promising are then brought along into 
more clinically relevant pain models. Thus, we used this assay to evaluate the analgesic effects of 
our pepducin series by testing PP-001, PP-003 and PP-005 (each presenting a distinct SPR profile) 
at a dose of 275 nmol/kg (Figure 3A). Please note that the pepducins were not degraded for at 
least 60-min in rat cerebrospinal fluid, as determined in an in vitro metabolic stability assay 
(Supplementary Figure S3). As can be seen, administration of the full-length pepducin (PP-001) 
resulted in a significant increase in the tail withdrawal latency, compared to vehicle-treated 
animals, that began immediately following i.t. injection and lasted for 60 min. In contrast, PP-003 
was ineffective at increasing the reaction time of the rats in the tail-flick test. I.t. delivery of PP-
005 produced a significant antinociceptive effect that was weaker than PP-001’s. Notably, the 
antinociceptive actions of PP-001 and PP-005 were not accompanied by any observable side 
effects. Injections of NP-001 or PP-SCR-001 at the same dose did not result in a significant 
increase in the tail withdrawal latency (Figure 3B). In Figure 3C, we provide the response 
amplitude values at the 40 min-timepoint post-injection, where we can observe significant effects 
for PP-001 (33 ±  6% MPE) and PP-005 treatment (17 ± 4% MPE), compared to the vehicle 
condition (4 ± 2% MPE). NP-001 and PP-SCR-001 had no significant effects (10 ± 3% and 6 ± 
2% MPE, respectively).  
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Again, we should highlight the fact that the antinociceptive effects observed here occur when 
the pepducins are administered at 275 nmol/kg. For PP-001, this corresponds to 500 µg/kg. This 
high dose was chosen to reflect the shift in potency we expect for our pepducins, relative to 
traditional orthosteric ligands. Indeed, we previously reported the design of a NT(8-13) analogue, 
JMV2007 (compound 6), that binds NTS1 with an IC50 of 0.02 ± 0.002 nM, and increased tail-
withdrawal latencies when administered i.t. at a 30 µg/kg dose (Fanelli, et al., 2015). Likewise, we 
recently reported a novel series of macrocyclic NT(8-13) analogues and therein characterized a 
compound with a 15 ± 2 nM (Ki) binding affinity for NTS1, which we tested at various doses in 
our acute pain model. We found that it presented with an ED50 of 4.63 µg/kg and reached maximal 
efficacy at 10 µg/kg (Sousbie, et al., 2018). In comparison, the dose at which PP-001 was 
administered represents a 15 to 50-fold increase (relative to 10 and 30 µg/kg, respectively). As 
indicated previously, pepducins typically present with micromolar potencies in cell-based assays, 
whereas orthosteric ligands may often present with nanomolar potencies. Thus, we might 
reasonably expect a 100-fold shift in potency, simply as a result of the nature and mode of action 
of pepducins. Here, the fact that we clearly observe pepducin-induced antinociception in this 
model, at this dose, suggests that PP-001 and PP-005 are very effective at relieving pain. 
Accordingly, these pepducins were retained for further study into their analgesic properties. 
 
3.5 PP-001 attenuates formalin-induced nociceptive behaviors in the tonic pain model 
We next assessed the antinociceptive potential of these pepducins by using the formalin test as 
a model of tonic (or persistent) pain. As expected, intraplantar injection of formalin into the right 
hind paw of saline-pretreated rats induced a biphasic time-dependent increase in pain scores 
(Figure 4A). However, rats pre-injected with PP-001 (i.t., 275 nmol/kg) exhibited significantly 
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lower pain scores during the inflammatory phase. This reduction in spontaneous nociceptive-
related behaviors is also reflected in the total area under the curve (AUC) values calculated for the 
prolonged inflammatory phase (21-60 min) (Figure 4B), where we observe a 63 ± 14% decrease 
in PP-001-treated animals compared to the vehicle. PP-005 had a lesser, though still significant, 
antinociceptive effect in the tail-flick test; however, it proved to be ineffective at relieving pain in 
the formalin model (Figure 4C-D).   
In an effort to ensure that the antinociception observed by PP-001 is mediated in vivo by the 
target receptor NTS1 and not the result of non-specific actions on other membrane proteins, PP-
001 was co-administered with the NTS1 antagonist SR48692 at 10 µg/kg dose (i.e. 17 nmol/kg). 
Here, the co-administration of this NTS1 antagonist entirely reversed the PP-001-induced 
antinociception (Figure 4B). While this experiment is not sufficient to conclude on the specificity 
of this pepducin for its target receptor, it strongly suggests that the antinociceptive effects of PP-
001 are indeed mediated via NTS1. This is further supported by our earlier in vitro findings 
showing that PP-001’s activity in the SPR experiment is NTS1-dependent. This is an important 
aspect to consider, as there is some debate in the literature regarding pepducin target specificity 
and selectivity. One of the advantages initially attributed to the pepducin approach was the 
potential for high selectivity, as multiple pepducins were reported to distinguish between subtypes 
of a same receptor family (Covic, et al., 2002; Janz, et al., 2011). In certain cases, however, 
pepducins have been found to target multiple 7TMRs, such as the PAR4-derived pepducin P4pal-
10 that inhibits agonist-induced responses for a range of Gαq-coupled receptors, not only PAR4 
(Carr III, et al., 2016b).  
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3.6 PP-001 reverses mechanical hypersensitivity in rat models of chronic neuropathic and 
inflammatory pain  
Subsequently, the analgesic potential of the PP-001 pepducin was assessed in rat models of 
chronic neuropathic and inflammatory pain. The Chronic Constriction Injury (CCI) model, which 
consists in the loose ligation of the rat sciatic nerve, was first used to mimic chronic neuropathic 
pain. The development of mechanical allodynia was assessed using the von Frey test before as 
well as 7 and 14 days post-surgery. As shown in Figure 5A, the CCI rats developed tactile 
allodynia by day 7 post-surgery, as the mechanical thresholds decreased from a baseline of 15 g to 
5.1 ± 0.4 g, corresponding to 66 ± 3% paw withdrawal threshold reduction, compared to 
preoperative values. On day 14 post-surgery, i.t. injection of PP-001 produced robust anti-
allodynic effects, reaching up to 84 ± 16% of pain relief at maximum effect.  
We further evaluated the analgesic efficacy of PP-001 in a model of chronic inflammatory pain 
following Complete Freund’s Adjuvant (CFA) intra-plantar injection into the right hind paw. The 
heat-inactivated mycobacteria (M. butyricum) present in the CFA provoke a strong immune 
response, which subsequently results in hypersensitive reactions to mechanical stimuli. On day 7 
post-CFA injection, the paw withdrawal thresholds in response to tactile stimuli greatly decreased 
from 15 g in naïve animals to 3.0 ± 0.2 g in CFA rats (i.e. 80 ± 2% reduction in paw withdrawal 
thresholds). Importantly, i.t. injection of PP-001 (275 nmol/kg) significantly reversed the 
mechanical inflammatory pain hypersensitivity on day 12 post-CFA injection (60 ± 14%), thus 
confirming the analgesic activity of PP-001 in a variety of pain paradigms (Figure 5B). 
Prior to this work, NTS1 was untargeted by pepducin technology, and pain research was an area 
largely untouched. Indeed, very few studies have been published in which pepducins were 
administered in a pain paradigm. In 2009, McDougall and colleagues sought to decipher the role 
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of PAR4 in joint pain and inflammation and found that the PAR4-derived pepducin p4pal-10 could 
inhibit the thermal and mechanical hyperalgesia produced by intra-articular injection of a PAR4 
agonist (McDougall, et al., 2009, Russell, et al., 2009). Similarly, Annahazi and colleagues used 
p4pal-10 to investigate the role of PAR4 on visceral pain produced by colorectal infusion of fecal 
supernatants originating from patients with ulcerative colitis (UC) or irritable bowel syndrome 
(IBS) (Annahazi, et al., 2009). In this experimental condition, they found that p4pal-10 treatment 
exacerbated visceral sensitivity in UC-infused rats. We are aware of only one other study to use a 
pepducin in a pain context. In this study, a pepducin derived from the ICL2 of the delta opioid 
receptor (DOP), C11-DOPri2, reversed the analgesic action of deltorphin II in CFA-treated rats 
(Beaudry, et al., 2015). In each of these studies, the pepducins were used to inhibit agonist-
mediated effects, and thus have been described as antagonists of their cognate receptors. However, 
due to the allosteric nature of pepducins, we deem it more appropriate to describe them as negative 
allosteric modulators. Regardless, the pepducins were used as pharmacological tools to decipher 
the role of their target receptors in a specific pain context, or to better understand receptor-effector 
interactions. While pepducin treatment was not the focus of these studies, they nevertheless 
provided a basis for considering that pepducins might effectively modulate the pain response and 
thus might represent a valid strategy in pain-relief. Our findings lend further credence to this idea, 
as we report a pepducin (PP-001) that effectively reduces nociceptive behaviors in multiple pain 
models. Notably, this pepducin-mediated effect is maintained even in chronic pain states that are 
very challenging to treat. 
 
3.7 FP-001 reaches the dorsal root ganglia after i.t. delivery 
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It has previously been reported that the NTS1 receptor is expressed in the laminae I and II of 
the spinal cord dorsal horn, as well as in subpopulations of small- and medium-sized neurons in 
the dorsal root ganglia (DRGs) of naïve rats (Roussy, et al., 2008). As the DRGs house the cell 
bodies of primary afferents critical to pain sensation and transmission, we questioned whether or 
not PP-001 reached the primary sensory neurons following lumbar i.t. injection. In order to 
investigate this, we designed an ICL1-derived pepducin tagged with the TAMRA fluorophore in 
the N-terminal position, which we injected (i.t.) into rats at 275 nmol/kg. Twenty minutes post-
injection, the lumbar DRGs were isolated and fixed, and we observed TAMRA-associated 
fluorescence via confocal microscopy. As can be seen in Figure 6, a diffuse TAMRA staining was 
detected in the different subtypes of sensory neurons (small, medium and large) at the level of the 
L5-L6 vertebrae of pepducin-treated animals. This fluorescence was absent in vehicle-treated 
animals (Supplementary Figure S4). It is worth noting that all subtypes of DRG neurons are 
labeled after FP-001 injection, this can be explained by the fact that a pepducin anchors itself in 
any cell membrane regardless of the presence of the receptor but only signals when its target 
receptor is present. Furthermore, no staining was observed in the superficial laminae of the dorsal 
horn of the spinal cord. In order to ensure that the labeling of PP-001 with the TAMRA fluorophore 
did not alter its antinociceptive effects, we tested FP-001 in our acute pain model, and measured 
tail withdrawal latencies to a noxious thermal stimulus. We observed a similar increase in the tail 
withdrawal latency in FP-001-treated rats as with PP-001, with a maximal possible effect of 40 ± 
9% at 40 min post-injection. This data may suggest that when injected i.t., PP-001 modulates the 
pain response directly at the primary afferent nociceptors. 
In this study, we applied pepducin technology to the study and treatment of chronic pain, using 
NTS1 as a therapeutic target. We recognized that pepducins, by their very particular mode of 
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action, offer unique opportunities in drug discovery. Indeed, drug development in recent years has 
been profoundly impacted by concepts such as biased agonism and allostery (Kenakin, 2012), 
suggesting that we might be able to fine-tune 7TMR responses in order to produce desired 
therapeutic outcomes and limit undesirable effects (Kenakin, A Pharmacology Primer, 2009). 
Pepducins that act allosterically at the intracellular surface of 7TMRs are particularly interesting 
from this viewpoint, as they may access distinct receptor conformations unavailable to traditional 
orthosteric, or even extracellular allosteric ligands (Carr III, et al., 2014).  
The NTS1-derived pepducins presented here appear to act as allosteric agonists of NTS1, as 
evidenced by the BRET experiments monitoring G protein activation. However, the very distinct 
pepducin response profiles observed in the SPR assay indicate that their global effect on a cell 
population is very different to that produced by orthosteric activation of NTS1. Presumably, they 
may stabilize NTS1 receptor conformations that lead to distinct physiological responses, for which 
only a subset of the effects associated with NTS1 activation are produced (analgesia, hypotension, 
hypothermia, ileum contraction and relaxation, etc.). This hypothesis is supported by the 
observation that, contrarily to other NTS1 agonists, i.t. administration of PP-001 does not appear 
to produce hypothermia in male Sprague-Dawley rats. Indeed, spinal delivery of the NTS1 agonist 
PD149163 (16.5 nmol/kg) leads to a 1.6 ± 0.2oC drop in mean body temperature, whereas PP-001 
at 275 nmol/kg does not induce hypothermia (Supplementary Figure S5). Potentially, therefore, 
these pepducins could not only be of great therapeutic interest, but valuable as tools to decipher 
the signaling pathways responsible for NTS1’s different physiological effects, the mechanisms 
behind many of which remain unclear.   
However, it is evident that the in vitro and in vivo experiments we performed in this study 
represent a very preliminary characterization of the pepducins’ actions. To truly understand how 
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these pepducins modulate the NTS1 receptor, additional experiments should be performed to 
further explore both their cellular and physiological effects. As mentioned previously, it is also 
feasible that the pepducins in our series do not solely target NTS1, but also act on other 7TMRs 
and/or cellular effectors. However, the fact that PP-001 does not exhibit any activity when the 
receptor is absent in the SPR experiment, as well as the observation that co-administration of PP-
001 with the NTS1 antagonist SR48692 reverses its antinociceptive response, suggests that these 
actions are indeed mediated via its target receptor NTS1. 
 
4. Conclusions  
In this proof-of-concept study, we sought to determine whether pepducin technology is 
applicable to the study and treatment of chronic pain. We chose the NTS1 receptor as a novel 
template from which to design a pepducin series. Our findings indicate that these pepducins are 
biologically active, can engage NTS1-related signaling pathways at concentrations of 10 µM and 
can induce distinct DMR response profiles in a NTS1-expressing cell population. Most 
importantly, we found that the PP-001 pepducin can effectively relieve pain in acute, tonic and 
chronic pain models when injected (i.t.) at a 275 nmol/kg dose. This study represents a first foray 
into the field of pepducin-mediated pain-relief and may help inform the development of novel 
analgesics that could better cater to the needs of chronic pain patients.   
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Figures & Legends 
 
 
 
Figure 1. Activation of G protein signaling pathways in response to pepducin treatment, 
monitored by BRET2. Gαq (A) and Gα13 (B) protein activation in CHO cells transiently 
transfected with hNTS1 and the BRET2-based biosensors, 15 min post-stimulation with NT(8-13) 
(1 µM), the ICL1-derived hNTS1 pepducins or palmitate (10 µM). BRET2 ratios were normalized 
according to NT(8-13); values for non-treated cells were set as 0% pathway activation, and those 
for cells stimulated with 1 µM NT(8-13) were set as 100 % pathway activation. Data represent 
mean ± SEM, n = 3, performed in duplicate.
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Figure 2. Whole-cell integrated responses to pepducin treatment, monitored by surface plasmon resonance. Variations in 
reflectance (normalized response) observed by surface plasmon resonance in CHO-K1 cells stably expressing hNTS1, treated with 
NT(8-13) and each of the ICL1-derived hNTS1 pepducins (A-B), or with the controls NP-001 (B) and PP-SCR-001 (C) at a 10 µM 
concentration. Variations in reflectance observed in mock CHO-K1 cells (absent hNTS1 receptor) treated with NT(8-13) (D) or with 
PP-001 (E) at 10 µM. SPR was monitored for a 30-min period, during which time a steady signal was acquired for at least 10 minutes 
prior to compound stimulation. Data represent mean ± SEM, n = 6. Dotted line at x=0 represents time of compound stimulation. 
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Figure 3. Effects of ICL1-derived pepducins on rat acute pain (tail-flick test). Tail withdrawal 
latencies observed over a 90-min period in male Sprague-Dawley rats injected (i.t.) with pepducins 
PP-001, PP-003, or PP-005 (A), with control pepducins NP-001 and PP-SCR-001 (B), or with 
vehicle (saline, 10% DMSO, 20% PEG4000). All pepducins and controls were injected at 275 
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nmol/kg. The percentage of maximal possible effects (% MPE) of tail withdrawal were calculated 
at 40 min post-injection, for each condition (C). Data represent mean ± SEM, n = 6-12 rats per 
group. A two-way ANOVA with Tukey’s correction for multiple comparisons was performed (A-
B). A Kruskal Wallis test with Dunn’s correction for multiple comparisons was also performed 
(C). Asterisks denote statistical differences between the vehicle and PP-001-treated group: *, p < 
0.05; **, p < 0.01; ***, p < 0.001. Sharps denote statistical differences between the vehicle and 
PP-005-treated group: ##, p < 0.01. 
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Figure 4. Analgesic effects of ICL1-derived pepducins PP-001 and PP-005 on rat tonic pain 
(formalin test). Nociceptive responses, expressed as weighted pain scores, of male Sprague-
Dawley rats following subcutaneous injection of formalin in the right hind paw. Five minutes prior 
to formalin administration, rats were injected (i.t.) with vehicle (saline, 10% DMSO, 20% 
PEG4000), with PP-001 (275 nmol/kg), with PP-001 (275 nmol/kg) and NTS1 antagonist 
SR48692 (10 µg/kg) (A), or with PP-005 (275 nmol/kg) (C). The cumulative nociceptive response, 
expressed as mean of area under the curve (AUC), observed during the second (inflammatory) 
phase of the formalin test (21-60 min) (B, D). Data represent mean ± SEM, n = 6-12 rats per group. 
A two-way ANOVA with Tukey’s correction for multiple comparisons (A, C), and a Kruskal-
Wallis test with Dunn’s correction (B, D), were performed.  **, p < 0.01; ***, p < 0.001.   
0 10 20 30 40 50 60
0
1
2
3
Time (min)
Pa
in
 s
co
re
PP-001Vehicle PP-001 + SR48692
✱✱
Ve
hic
le
PP
-00
1
PP
-00
1 +
 SR
48
69
2
0
20
40
60
A
re
a 
un
de
r t
he
 c
ur
ve
 (A
U
C
)
Inflammatory Phase
✱✱ ✱✱✱
A B
0 10 20 30 40 50 60
0
1
2
3
Time (min)
Pa
in
 s
co
re
PP-005Vehicle 
Ve
hic
le
PP
-00
5
0
10
20
30
A
re
a 
un
de
r t
he
 c
ur
ve
 (A
U
C
)C D
 50 
 
 
 
Figure 5. Analgesic effects of ICL1-derived pepducin PP-001 on rat chronic neuropathic and 
inflammatory pain. Mechanical allodynia thresholds in male Sprague-Dawley rats following 
ligation of the sciatic nerve (Chronic Constriction Injury (CCI) model) (A) or following hind paw 
injection with Complete Freund’s Adjuvant (Complete Freund’s Adjuvant (CFA) model) (B), as 
determined by von Frey test. Testing was performed prior to intervention (BL), and on days 7, 12 
(CFA) or 14 (CCI) post-intervention. Rats were injected (i.t.) with PP-001 (275 nmol/kg) or with 
vehicle (saline, 10% DMSO, 20% PEG4000) on Days 12/14 and observed over a 1-hour period. 
Thresholds depicted correspond to the operated (ipsilateral) limb. Data represent mean ± SEM, 
with a n = 5 (CCI) or n = 6 (CFA) rats per group. A two-way ANOVA with Sidak’s correction for 
multiple comparisons was performed. ****, p < 0.0001. 
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Figure 6. Detection of fluorescent pepducin FP-001 in rat dorsal root ganglion neurons 
following i.t. injection. Confocal microscopy images of DRG neurons extracted at the level of the 
L6 vertebrae from rats injected (i.t.) with the TAMRA-labeled pepducin FP-001 (275 nmol/kg, n 
= 5 rats). TAMRA-associated fluorescence was visualized in the red filter channel. DAPI (blue) 
was used as a nuclear counterstain. Confocal images were acquired under 20x magnification 
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(upper panel; Scale bar = 80 µm) and 40x magnification (lower panel; Scale bars = 40 µm). (A). 
Tail withdrawal latencies observed over a 60-min period in male Sprague-Dawley rats injected 
(i.t.) with FP-001 (275 nmol/kg) or with vehicle (saline, 10% DMSO, 20% PEG4000) (n = 3 rats) 
(B). The percentage of Maximal possible effect (% MPE) of tail withdrawal were calculated at 40 
min post-injection, for each condition (C). Data represent mean ± SEM. A two-way ANOVA with 
Sidak’s correction for multiple comparisons was performed (B). **, p < 0.01. 
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Supplementary Scheme S1. Structure of the pepducins PP-001 - PP-005 
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Supplementary Scheme S2. Structure of the control pepducins 
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Supplementary Material and Methods 
 
Evaluating PP-001 cytotoxicity 
Cell viability was assessed using the Cell Titer-Glo Luminescent Assay kit (Promega Corporation, 
Madison, WI, USA) according to manufacturer’s instructions. Briefly, CHO-hNTS1 were seeded 
onto white opaque 96-well plates (BD Falcon, Corning, NY, USA) at 35 000 cells per well (100 
µL). Twenty-four hours post-seeding, the cells were treated with the vehicle (serum-starved 
DMEM-F12 media) or with 10 µM PP-001, at a total volume of 100 µL per well. Additional wells 
received 100 µL of vehicle only (no cells) as a control. Incubation time was set for 16 hours. The 
plates were removed from incubator 20 min prior to assay in order to reach room temperature, and 
wells were treated with 100 µL of Cell Titer-Glo Reagent previously thawed to room temperature. 
Plates were set on a nutating mixer for 2 min and incubated at room temperature for an additional 
10 min. Total luminescence counts were read on a GENios Pro plate reader (Tecan, Durham, NC, 
USA). Luminescence counts were normalized: the luminescence from the vehicle-treated 
condition was set as 100% cell viability, and the luminescence from the vehicle only condition (no 
cells) set as 0% cell viability. Data represent mean ± SEM, n = 2, tested in quadruplicate. 
 
 
Evaluating stability of PP-001 in rat cerebrospinal fluid and plasma 
 
CSF was sampled from anesthetized rats directly from the cistern magna. CSF was frozen at -20˚C 
until use. Plasma was sampled from anesthetized rats by cardiac puncture in 4.5 mL plasma 
separating tubes coated with lithium heparin (from BD). Tubes were then centrifuged at 2500 rpm 
for 15 min at 4˚C to separate the plasma from the blood cells. Plasma was aliquoted and stored at 
-80˚C until use. 
 S6 
Stability assay was performed by adding 6 µL of PP-001 (1 mM) to 27 µL of either CSF or plasma. 
After mixing, the reaction was incubated at 37˚C for 60 min. Reaction was stopped over ice and 
25 µL of 5% formic acid was added to separate the compound bound to plasma proteins. Then 100 
µL of acetonitrile containing 0.25 mM N-N-dimethylbenzamide (as an internal standard) was 
added to precipitate all the proteins. The mixture was vortexed and centrifuged at 13,000 g for 30 
min at 4˚C. Supernatant was filtered through 0.22 µm PTFE filters, diluted with 80 µL of ddH2O 
and analized by UPLC/MS (Waters UPLC system coupled with a SQ detector 2 and a PDA eλ 
detector, coupled to an Acquity UPLC BEH C4 column, 2.1 mm X 50 mm, 1.7 µm spherical size) 
using the following gradient: water + 0.1% TFA and acetonitrile (0 → 0.2 min, 5% acetonitrile; 
0.2 → 1.5 min, 5% → 95%; 1.5 → 1.8 min, 95%; 1.8 → 2.0 min, 95% → 5%; 2.0 → 2.5 min, 
5%). Quantification was done by determining the AUC (area under the curve) ratio of PP-001 over 
the AUC of the internal standard.  
 
Monitoring animal core-body temperature 
Body temperature was measured using a thermistor probe inserted into the rectum of adult 
Sprague-Dawley rats. Prior to testing, animals were individually acclimatized to manipulations 
and thermistor probe 5 min/day for three consecutive days. On the test day, temperature was 
measured before (baseline) and 75 min following i.t. injection of saline, PP-001 at 275 nmol/kg or 
the NTS1-selective reference compound PD149163 (1). Variations in body temperature (Δ body 
temp, degrees Celsius) were determined as changes from baseline for each individual animal. 
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Supplementary Figure S1. Absence of Gαq protein signaling pathway activation in mock 
CHO cells in response to pepducin treatment, monitored by BRET2.  Gαq protein activation 
in CHO-K1 cells transiently transfected with the BRET2-based biosensors, 15 min post-stimulation 
with NT(8-13) (1 μM) or with the ICL1-derived hNTS1 pepducins (10 µM). BRET2 ratios at 15 
min post-stimulation were subtracted from those at baseline for each condition in order to obtain 
the ΔBRET2. In this paradigm, a decrease in BRET2 corresponds to G protein activation. Data 
represent mean ± SEM, n = 2, performed in duplicate.  
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Supplementary Figure S2. Absence of cytotoxicity in PP-001-treated cells, 16 hours post-
stimulation. Cell viability of CHO-hNTS1 cells incubated for 16 hours with the vehicle (serum-
starved DMEM-F12 media) or with PP-001 at a 10 µM concentration, assessed using the Cell 
Titer-Glo Luminescent Assay kit by Promega. Data represent normalized luminescence counts: 
luminescence from the vehicle-treated condition was set as 100 % cell viability, and luminescence 
from the vehicle only condition (no cells) set as 0 % cell viability. Data represent mean ± SEM, n 
= 2, tested in quadruplicate.  
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Supplementary Figure S3. Stability of PP-001 pepducin in rat cerebrospinal fluid and 
plasma. Quantification by UPLC/MS of PP-001 pepducin before and after a 60-min incubation 
period at 37oC in rat cerebrospinal fluid (CSF) and in rat plasma. Data represents mean ± SEM, n 
= 3 independent samples per condition. 
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Supplementary Figure S4. Absence of TAMRA-associated fluorescence in dorsal root 
ganglion neurons of vehicle-treated rats. Confocal microscopy images of dorsal root ganglion 
cells extracted at the level of the L6 vertebrae from rats intrathecally injected with the vehicle 
(saline, 10% DMSO, 20% PEG) (n = 5 rats). TAMRA-associated fluorescence was visualized in 
the red filter channel. DAPI (blue) was used as a nuclear counterstain. Images were acquired under 
40x magnification. 
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Supplementary Figure S5. Effect of PP-001 on rat core body temperature. Rat core body 
temperature changes (in degrees Celsius) induced by i.t. injection of vehicle, PP-001 (275 
nmol/kg) or the NTS1-selective agonist PD149163 (16.5 nmol/kg). Baseline body temperature 
assessment was performed before i.t. injection. Error bars represent mean ± SEM, n= 6 animals 
per group. A Kruskal Wallis test with Dunn’s correction for multiple comparisons was performed. 
Asterisks denote statistical differences between the vehicle and the PD149163-treated group: **, 
p < 0.01 
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